Attovia Therapeutics, Inc. (NASDAQ:ATTO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) have been given an average rating of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $42.20.

Several equities research analysts have recently commented on ATTO shares. Royal Bank Of Canada began coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective for the company. Citigroup initiated coverage on Attovia Therapeutics in a report on Monday, August 31st. They set a “buy” rating and a $30.00 price target for the company. Leerink Partners began coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $52.00 price target for the company. Morgan Stanley assumed coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “overweight” rating and a $39.00 price objective on the stock. Finally, Lifesci Capital began coverage on Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $45.00 price objective on the stock.

Insider Activity at Attovia Therapeutics

In other news, Director Colin Walsh purchased 500,000 shares of the stock in a transaction on Thursday, August 6th. The shares were acquired at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the completion of the acquisition, the director directly owned 3,020,632 shares of the company’s stock, valued at $51,350,744. This trade represents a 19.84% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the transaction, the insider owned 6,154,213 shares of the company’s stock, valued at approximately $104,621,621. This trade represents a 10.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 2,740,587 shares of company stock worth $47,269,979 in the last 90 days.

Attovia Therapeutics Stock Performance

NASDAQ ATTO opened at $23.66 on Wednesday. Attovia Therapeutics has a 1-year low of $16.15 and a 1-year high of $28.00.

Attovia Therapeutics (NASDAQ:ATTO) last announced its earnings results on Wednesday, September 2nd. The company reported ($4.88) EPS for the quarter. The business had revenue of $0.45 million for the quarter. As a group, analysts forecast that Attovia Therapeutics will post -4.06 earnings per share for the current fiscal year.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.